Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first-in-class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. The company is also developing cell therapy platforms, including CellPryme, a high-performance cell therapy enhancement platform; and OmniCAR, is a platform seeks to overcome the challenges of conventional CAR-T therapy including manufacturing, safety and reliability. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.
Price analytics
Returns
1 day
0.0%
1 week
-2.9%
1 month
-1.5%
3 months
-12.0%
6 months
17.9%
1 year
50.0%
3 years
15.8%
Risk
Volatility (1y ann.)
91.7%
Beta vs ASX 200
1.14
Sharpe (1y)
0.84
VaR 95% (1-day)
-7.6%
Max drawdown (1y)
-52.4%
Off 1-year high
-37.1%
Technicals
RSI(14)
53
vs 50DMA
-10.8%
vs 200DMA
-4.7%
Trend
Golden cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value71.0
Trailing P/E
—
Forward P/E
100
PEG ratio
—
EV / EBITDA
100
Price / Book
46
Price / Sales
0
Growth0.0
Revenue growth (1y)
0
Revenue CAGR (3y)
—
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health69.2
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
0
Current ratio
100
Debt / Equity
100
Quality (Profitability & Cash Flow)0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income—
No meaningful dividend — pillar excluded from the overall score.
Momentum46.9
6-month return vs ASX 200
100
Price vs 200-day average
34
Price vs 50-day average
0
Position in 52-week range
30
Hover a row's info icon for the exact rule. Bounds and weights are configurable in
the Django admin (Scoring configuration).